GFR vs VET

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for GFR crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.

Following a +4.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where GFR advanced for three days, in 126 of 164 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

The Aroon Indicator entered an Uptrend today. In 77 of 103 cases where GFR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 34 cases where GFR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GFR as a result. In 45 of 56 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for GFR turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 30 similar instances when the indicator turned negative. In 25 of the 30 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

GFR moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GFR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.289) is normal, around the industry mean (3.856). P/E Ratio (-17.162) is within average values for comparable stocks, (4.063). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.958). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (1.755) is also within normal values, averaging (5.980).

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. GFR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GFR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for VET crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.

Following a +4.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where VET advanced for three days, in 230 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

Bearish Trend Analysis

The 10-day RSI Indicator for VET moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 22 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 63%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 67 cases where VET's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 69%.

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VET as a result. In 68 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.

The Moving Average Convergence Divergence Histogram (MACD) for VET turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 38 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.

VET moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VET declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

VET broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.881) is normal, around the industry mean (3.856). P/E Ratio (-4.300) is within average values for comparable stocks, (4.063). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (1.958). Dividend Yield (0.031) settles around the average of (0.044) among similar stocks. P/S Ratio (1.349) is also within normal values, averaging (5.980).

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. VET’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VET’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.